European review of Fabry disease treatments

The EMEA accepted for review TKTX's MAA for its Replagal agalsidase enzyme replacement therapy for Fabry disease. Separately, GENZ said Europe's CPMP began reviewing its MAA for Fabrazyme agalsidase b...